Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990135 | 0.87 | NR3C2 (0.30) | NR3C2 | |
| SCHEMBL19989744 | 0.85 | SYK (0.43) | PRMT1AURKARPS6KB1SYKMAPT | |
| SCHEMBL19990040 | 0.83 | ATR (0.34) | PRMT1AURKARPS6KB1SYKMAPT | |
| SCHEMBL19989853 | 0.77 | SYK (0.34) | AURKARPS6KB1SYKMAPTSMN1; SMN2 | |
| SCHEMBL30992737 | 0.70 | PDPK1 (0.33) | SYKGPR119PDPK1 | |
| SCHEMBL30992820 | 0.69 | TRPV1 (0.35) | SYKGPR119PDPK1 | |
| SCHEMBL29893949 | 0.68 | NR3C2 (0.36) | MAPTNR3C2LMNAALDH1A1 | |
| SCHEMBL19990011 | 0.68 | ALDH1A1 (0.47) | AURKAMAPTALDH1A1 | |
| SCHEMBL15274739 | 0.68 | PDPK1 (0.40) | SYKPDPK1ALDH1A1 | |
| SCHEMBL19989939 | 0.68 | SYK (0.40) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT1 | PRMT1 562/4885AURKA 135/4885RPS6KB1 73/4885 |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, AKT1 | PRMT1 562/4885AURKA 135/4885RPS6KB1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.